AOD-9604 is a modified fragment of human growth hormone studied for its proposed fat-metabolism effects without the broader growth-promoting activity of full-length HGH. Clinical trials for obesity did not demonstrate sufficient efficacy for approval, and it remains an unapproved research compound.
AOD-9604 is a small fragment of growth hormone, engineered to keep GH's fat-burning effect while leaving out the parts that raise blood sugar or drive tissue growth.
The short version: animal studies showed a strong fat-loss effect, an early human trial showed a smaller but real one — but the compound's own drug-development program was later discontinued after larger trials couldn't reproduce it at scale. That last part matters as much as the promising early data.
Animal studies: daily oral dosing for 19 days cut body-weight gain by over 50% compared to untreated animals, with increased fat-burning activity and — unlike regular GH — no downside to insulin sensitivity. Metabolic studies of AOD9604, Horm Res, 2000
Early human trial (n=71, 12 weeks, 1mg oral dose): found 2.8kg lost vs. 0.8kg on placebo, plus improved glucose tolerance. Worth flagging: this particular citation couldn't be independently re-verified this pass, so treat it with a little more caution than the animal data above.
Why this matters: a much larger follow-up trial (300+ people, testing doses from 1-30mg) found no benefit to going higher than 1mg — and a later 536-person trial failed to show meaningful weight loss at all. The drug was ultimately shelved as an obesity treatment. That doesn't erase the earlier results, but it's the honest context for how much weight to put on them.
The dose used in the positive human trial was 1mg/day, oral — and notably, testing higher doses (5-30mg) in the larger follow-up trial didn't work better, it worked worse. Animal studies used a different, weight-based dose (500mcg/kg/day), which doesn't translate directly to a human oral dose. No dose from this compound has been confirmed effective in a large trial — that's a real caution, not a minor footnote.
No specific side-effect data has been independently verified yet for this compound. Its development program was discontinued because later trials didn't show it working reliably at scale — not because of a safety problem. Worth keeping those two things separate: this isn't a clean bill of health, and it isn't a safety red flag either — it's simply unconfirmed.
No. It was trialed for obesity but did not demonstrate sufficient efficacy to gain approval, and it is sold today as a research compound only.
Fat metabolism and lipolysis, based on it isolating a specific region of the HGH molecule proposed to drive fat breakdown without growth effects.
It is designed to isolate the fat-metabolism fragment of HGH specifically, distinct from the growth-promoting activity of full-length growth hormone.
Close, but not identical. AOD-9604 is essentially an optimized version of HGH Fragment 176-191 — same core region of the growth hormone molecule, with a modification that made it stable enough to actually reach formal trials. They get used interchangeably in a lot of research writing, but AOD-9604 is technically the more refined compound.
Less convincingly than the marketing suggests, honestly. It looked promising in early animal and lab-tissue studies, but its largest human clinical trial didn't show statistically significant weight loss, and it was dropped as a drug candidate back in 2007. The human data that does exist points to modest results — kilograms, not the double-digit changes sometimes implied.
Mostly the appeal of the concept — marketed as targeting fat metabolism specifically without the broader effects of raising overall GH. Genuinely attractive pitch, even though the human efficacy data hasn't really held up to it.
Looking for something specific, or placing a wholesale order? Send us a DM or email.